We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx)
Summary
We reported previously on the widespread occurrence of anti-HLA alloantibodies of the IgA isotype (anti-HLA IgA) in the sera of solid-organ re-transplantation (re-tx)
candidates (Arnold et al., 2013) . Specifically focussing on kidney re-tx patients, we now extended our earlier findings by examining the impact of the presence and donor specificity of anti-HLA IgA on graft survival. We observed frequent concurrence of anti-HLA IgA and anti-HLA IgG in 27% of our multicenter collective of 694 kidney re-tx patients. This subgroup displayed significantly reduced graft survival as evidenced by the median time to first dialysis after transplantation (TTD 77 months)
| INTRODUC TI ON
Chronic antibody-mediated graft rejection (AMR) is a major cause for late loss of transplant function (Einecke et al., 2009; Gaston et al., 2010; Lee et al., 2002; Sellares et al., 2012) . Accordingly, the presence of antibodies specific to allogenic human leukocyte antigen (HLA) in the serum of recipients is strongly associated with an increased risk of graft failure. Therefore, detection of donor-specific alloantibodies of the immunoglobulin G (IgG) subclasses is an integral component of most current AMR risk stratification strategies after kidney transplantation. Recently, however, the impact of other complement-fixing and also noncomplement-fixing antibody isotypes on graft survival has gained attention (Chen, Sequeira, & Tyan, 2011) . As part of the 16th International HLA and Immunogenetics Workshop, we reported a high prevalence of anti-HLA IgA in a large cohort of re-transplantation candidates (Arnold et al., 2013) .
Expanding these findings, we now assessed the impact of the presence and specificity of anti-HLA IgA alloantibodies on graft survival in a subset of 694 kidney re-transplantation patients.
| MATERIAL S AND ME THODS

| Patients and study design
Sera from 694 patients collected for our previous report (Arnold et al., 2013) of the 16th International HLA and Immunogenetics Workshop (IHIW) were selected for this follow-up study based on the following criteria: (i) history of at least one previous failed kidney graft, (ii) listed for kidney re-transplantation and (iii) availability of date of previous kidney transplantation and first dialysis after previous transplantation. Of note, inclusion of patients was irrespective of cause of rejection and previous screening results. We employed the median time to first dialysis after transplantation (TTD) as a measure for graft function failure. Data were provided directly from the centers (Basel, Bangkok) were typed for HLA-A, -B and -DR, 571 for HLA-DQ, and 439 for HLA-C (Table 1) . A total of five donors had no available typing data and were therefore excluded from the analysis of donor specificity.
The number of mismatched HLA-loci for each transplantation was determined by comparing the split level HLA type of recipient and donor for HLA-A, -B, -DR and -DQ. 
| Serum IgA levels
| Antibody screening and specification
All sera were tested for the presence and specificity of anti-HLA IgG and IgA as previously described (Arnold et al., 2013 Bonferroni-corrected p-value cut-off (of p = .017 for 3 and p = .0083
| Statistical analyses
for four subgroups) was used to assert statistical significance.
| RE SULTS
| Anti-HLA IgA antibodies are frequent in renal re-transplantation candidates
For this follow-up study, 694 kidney re-transplantation patients were selected from a cohort of 803 patients collected for the 16th IHIW workshop based on serum and TTD availability (Arnold et al., 2013) . Despite exclusion of all nonkidney re-transplantation candidates from the original cohort, demographics, HLA typing coverage as well as antibody prevalence in this sub-cohort are comparable to our earlier report (Table 2) . Specifically, anti-HLA antibodies of the IgG and/or IgA isotype were detectable in 547 (79%) patients.
Stratifying by isotype revealed that 333 (48%) patients carried anti HLA-IgG exclusively. Moreover, 29 (4%) and 185 (27%) patients carried either anti-HLA IgA or anti-HLA antibodies of both isotypes respectively (Table 2, Figure S1 ). Therefore, a total of 31% of patients had detectable anti-HLA IgA antibodies in the serum, raising the question of the relevance of IgA in general and anti-HLA IgA in particular for graft survival.
| Total serum IgA levels do not impact graft survival in kidney re-transplantation candidates
Early studies hinted at a positive correlation of elevated serum
IgA levels with enhanced kidney transplant survival Koka et al., 1993) . In addition, a correlation between anti-HLA IgA and total serum IgA was also proposed .
Therefore, we first measured total serum IgA levels in our cohort of 694 kidney re-transplant candidates and assessed the effect on Figure 1 ), diverging from earlier observations in pretransplantation sera . Taken together, our data demonstrate that total serum IgA levels in renal re-transplantation candidates are globally similar to normal levels and not significantly associated with transplantation outcome.
| Presence of anti-HLA IgA antibodies correlates with reduced graft survival after kidney re-transplantation
As total IgA serum levels did not significantly correlate with graft survival, we further investigated the impact of anti-HLAspecific antibody isotype status on TTD in our patients. Of note, TTD was significantly shorter in patients tested positive for anti-HLA IgG antibodies (93.7 months), as well as, anti HLA-IgA (81.7 months) compared to patients without either anti-HLA isotype (118.5 months, Figure 2a ). In addition, patients with TTD below the median TTD of 98.8 months were significantly enriched in the anti-HLA IgA positive group (Table 3) . This indicates that
IgA-positive patients had a higher risk for earlier graft rejection (relative risk 1.6, 95% CI: 1.3-2.0, p < .0001). Indeed, this is also apparent from the slope of the Kaplan-Meyer plots which show an earlier decline in the number of patients without dialysis in the IgA-negative subgroup (Figure 2a ). The limiting number of patients in the study precluded multivariate analysis of anti-HLA IgA status and other factors known to contribute to graft loss. Univariate analyses, however, revealed no significant association of either gender or age with the presence of anti-HLA IgA antibodies (Table   S1 , Figure S2 ). In contrast, the number of HLA mismatches in the IgA-negative subcohort (mean 3.3, 95% CI: 3.1-3.5) was significantly lower than in the IgA-positive subcohort (mean 3.8, 95% CI:
3.5-4.0, p = .033). Conversely, the average number of mismatches was also significantly higher among anti-HLA IgG-positive (3.6, 95% CI: 3.5-3.8) compared to negative patients (2.9, 95% CI: 2.6-3.2, p < .0001, Figure S3 ). IgA alloantibodies can supplement routine IgG testing to improve risk stratification for kidney transplantations. However, effective treatment strategies of chronic AMR still prove to be controversial and understudied (Fehr & Gaspert, 2012) . Accordingly, clinical impact of an improved stratification remains largely speculative. As our dataset did not include the cause for the loss of graft function, further studies are needed to examine whether IgA alloantibodies are specifically associated with any specific cause of graft loss like AMR.
For this study, we tested sera from patients with a previously failed graft who were relisted for transplantation. In addition, patients' sera were collected at or after the first dialysis after the subsequent transplantation (on average 48 months). Therefore, (Moroni et al., 2013) .
Moreover, post-transplantation IgA deposition appears to be associated with reduced graft function in IgA nephropathy patients (Lefaucheur et al., 2016) . Interestingly, another recent study including but not limited to IgA nephropathy patients found a similar association of post-transplantation IgA deposition and graft dysfunction (Sofue et al., 2015) . Therefore, prolonged IgA deposition is a plausible mechanism for a reduction in graft function eventually resulting in graft failure. In contrast to these studies, however, our analysis specifically focuses on anti-HLA IgA. Consequently, F I G U R E 3 Graft survival after stratification by IgA DSA status several points argue against increased IgA deposition as a major contributor to graft dysfunction in anti-HLA IgA-positive patients.
First, anti-HLA IgA likely represent a minor fraction of total serum
IgA. And second, we do not observe elevated IgA serum levels in IgA-positive compared to IgA-negative patients in our study.
Functional studies are therefore mandated to clarify if anti-HLA IgA contributes directly to graft failure and elucidate the mechanisms involved.
Several earlier studies established links between the presence of IgA autoantibodies against human immunoglobulin domains and good kidney graft survival (Susal, Kropelin et al., 1995; . Importantly, elevated total serum IgA was also proposed to be associated with the presence of anti-HLA IgA and enhanced 3-year graft survival at least in primary recipients . Taken Second, our observation period extended significantly beyond the initial 3 years after transplantation and therefore included many late graft rejection events unobserved in earlier studies. Therefore, our study significantly expands previous findings and, to our knowledge, is the largest systematic assessment of a correlation between presence and specificity of anti-HLA IgA and kidney graft survival.
Notably, anti-HLA IgA-positive patients displayed an elevated average number of HLA mismatches compared to IgA-negative patients, while age and gender were not correlated with the presence of anti-HLA IgA. An increase in the number of HLA mismatches clearly represents a potential confounding effect for the observed shorter TTD (Opelz & Dohler, 2007) . However, anti-HLA IgG-positive patients in our cohort were also characterized by an increased number of HLA mismatches compared to anti-HLA IgG-negative patients. Therefore, our data are in line with a nonisotype-specific positive correlation of the degree of immunization and the development of anti-HLA antibodies, rather than a specific correlation with IgA. Nevertheless, a larger study allowing for multivariate analyses will be required to investigate dependency of covariates, including anti-HLA IgA, contributing to graft loss. Alternatively, longitudinal studies can permit assessment of the timing of IgG and IgA antibody development after transplantation. In the context of such studies it would be particularly interesting to compare and contrast IgG and IgA antibody (donor-) specificities, which would also help clarify a possible interdependence of anti-HLA IgG and IgA antibodies.
In summary, our study demonstrates significantly reduced kidney graft survival for patients carrying anti-HLA IgA and IgG alloantibodies in a large multicenter cohort of patients with previously failed grafts. Therefore, inclusion of anti-HLA IgA screening in postand potentially pretransplantation testing can be advisable for improved risk stratification for kidney transplantations.
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